Sunesis Pharmaceuticals to Present at 28th Annual Credit Suisse Healthcare Conference
November 08 2019 - 6:00AM
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that
Willie Quinn, Chief Financial Officer and Senior Vice President,
Finance and Corporate Development of Sunesis, will present at the
28th Annual Credit Suisse Healthcare Conference on Wednesday,
November 13, 2019 at 11:30 AM Mountain Time in Scottsdale, Arizona.
A live webcast of the presentation will be
available on the Sunesis website
at http://ir.sunesis.com. A replay will be archived on
the "Calendar of Events" page in the Investors and Media section of
the Sunesis website for two weeks.
About Sunesis
Pharmaceuticals
Sunesis is a biopharmaceutical company
developing novel targeted inhibitors for the treatment of
hematologic and solid cancers. Sunesis has built an experienced
drug development organization committed to improving the lives of
people with cancer. The Company is focused on advancing its novel
kinase inhibitor pipeline, with an emphasis on its oral
non-covalent BTK inhibitor vecabrutinib. Vecabrutinib is currently
being evaluated in a Phase 1b/2 study in adults with chronic
lymphocytic leukemia and other B-cell malignancies that have
progressed after prior therapies.
For additional information on Sunesis, please
visit www.sunesis.com.SUNESIS and the logos are trademarks of
Sunesis Pharmaceuticals, Inc.
Investor and Media Inquiries: |
Maeve Conneighton |
|
|
Willie Quinn |
Argot Partners |
|
|
Sunesis Pharmaceuticals Inc. |
212-600-1902 |
|
|
650-266-3716 |
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Sunesis Pharmaceuticals Inc (NASDAQ): 0 recent articles
More News Articles